Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placebo
- 1 January 1986
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 31 (2), 247-250
- https://doi.org/10.1007/bf00606669
Abstract
The antihistaminic effect of loratadine (160 mg) was compared in twenty-four normal male volunteers to chlorpheniramine maleate (4 mg) and placebo in a double blinded 3-way cross-over study of latin square design. After receiving single oral doses of each medication, the wheal response to serial 0.1 ml intradermal histamine (2 µg) and saline (control) injections were recorded over a 24-h period. The calculated wheal areas were compared to baseline measurements. The results were analyzed by analysis of variance. Loratadine exhibited a more pronounced inhibition of histamine wheal formation than placebo or chlorpheniramine maleate (pn=2; chlorpheniramine,n=3; and loratadine,n=1), the relative incidence were not statistically significant.This publication has 4 references indexed in Scilit:
- Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamineInflammation Research, 1984
- A comparison of triprolidine and clemastine on histamine antagonism and performance tests in man: Implications for the mechanism of drug induced drowsinessEuropean Journal of Clinical Pharmacology, 1975
- The evaluation of histamine antagonists in manEuropean Journal of Clinical Pharmacology, 1971
- A new approach to the use of histamine skin tests in the study of antihistamine drugsClinical Pharmacology & Therapeutics, 1969